Daily Pick

2026-06-01 · BMY

2026-06-01

Bristol-Myers Squibb BMY

Healthcare · Pharmaceuticals

Buy
Rec price$54.93
Target$64.00
Upside16.5%
Fwd P/E9.3
FCF yield13.7%
Div yield4.6%
Valuation
9/10
Growth
6/10
Financial Strength
7/10
Momentum
5/10
Catalyst
8/10

Snapshot

Metric Value
Price (~June 1, 2026) ~$54.93
Market cap ~$112B
Forward P/E ~9.3
FCF yield ~13.7%
2026 revenue guide $46.0–$47.5B (ahead of consensus)
2026 non-GAAP EPS guide $6.05–$6.35
Q1 2026 actual Revenue +1% YoY to $11.5B; growth portfolio +9%
Dividend $2.52/yr → ~4.6%+ yield, 17 consecutive annual hikes
Median analyst PT $64 (consensus "Hold"); Citi raised to $66
Implied upside to median PT ~16% + dividend → ~21% total return

Why the market may be mispricing it

Stock trades at a high-single-digit forward P/E vs. a healthcare sector that normally clears mid-teens. The headline drag is well-known: Eliquis loses U.S. exclusivity April 2028, Opdivo loses EU protection mid-2028, Revlimid is already off-patent. Together those drugs are ~45% of revenue and the LOE wave could affect ~64% of FY25 revenue by end of decade.

What the multiple isn't crediting:

  • Growth portfolio grew 9% in Q1 2026; management says full-year tracking the upper end of guidance.
  • Cobenfy (schizophrenia, +potential Alzheimer's psychosis label) hitting ~90% Medicaid coverage; management called for "breakout" status in 2026.
  • $2B cost-out program targeted for completion by end of 2027 — aligned with Opdivo LOE.
  • 12 registrational data readouts from 8 assets in 2026.
  • AI-driven oncology collaboration with Microsoft as a pipeline accelerator.

Catalysts

  • 3 mo: Cobenfy quarterly print + Q2 2026 earnings against an already raised bar.
  • 6 mo: Milvexian (Factor XIa anticoagulant) pivotal data; admilparant in IPF.
  • 12 mo: Cobenfy in Alzheimer's-related psychosis readout; iberdomide PFS data; multiple oncology updates.
  • 24 mo: Eliquis U.S. LOE arrives (April 2028) — replacement portfolio's contribution becomes measurable.

Bull / Base / Bear

  • Bull (~$75–80): Cobenfy ramps to multi-billion peak sales, ≥2 of 12 readouts surprise positively, multiple re-rates to ~12–13x forward. ~35–45% upside + dividend.
  • Base (~$62–66): Aligned with sell-side. Pipeline executes adequately, guidance hits high end, multiple drifts to ~10–11x. ~15–20% + 4.6% dividend.
  • Bear (~$42–46): Cobenfy stalls or a high-profile readout fails, Eliquis erosion worse than feared, multiple compresses to ~7–8x. ~15–20% downside.

Peer comparison

BMY PFE KHC NKE
Forward P/E ~9.3 ~8.9 ~8.9 trailing ~28
EV/EBITDA peer band 7.7 7.83 18.3
FCF yield ~13.7% ~5% trailing loss ~1.5%
Dividend 4.6%+ 6.82% 6.7% low
Catalyst density 2026 12 readouts moderate none structural turnaround, no hard catalysts

Why BMY beats each peer: PFE is similarly cheap but lacks BMY's catalyst density and Cobenfy-grade growth asset. KHC is cheaper but the business is shrinking (negative organic sales guide). NKE looks cheap only on DCF; on cash-flow multiples it's still rich and EPS is collapsing.

What would make the thesis wrong

  • Failed Cobenfy Alzheimer's-psychosis readout + U.S. label limitations on schizophrenia.
  • Milvexian Phase 3 miss.
  • Eliquis pricing/volume erosion arriving before April 2028.
  • Dividend cut.

Risks

  1. LOE math doesn't work — replacement portfolio under-delivers.
  2. Cobenfy disappoints — slower ramp, label expansion fails.
  3. Drug pricing reform / TrumpRX compresses the existing book.
  4. Pipeline readout failure — with 12 reads, base rates say some miss.
  5. Dividend coverage if FCF compresses post-2028.

Verdict — Buy (not Strong Buy)

Patent-cliff math is genuinely unresolved until pipeline data lands and a Cobenfy disappointment is a real left-tail. But on a risk/reward basis — cheap on cash flow, paid 4.6% to wait, dense 2026 catalyst calendar, and management already raising the bar — it's the cleanest setup in today's screened universe.

Why this ranked #1 today

The only name in the screened universe that combines (a) high-single-digit forward P/E and double-digit FCF yield, (b) a business that is already growing (Q1 +1%, growth portfolio +9%) rather than shrinking, (c) guidance recently raised and currently tracking the high end, and (d) a concentrated 2026 catalyst calendar (12 readouts + Cobenfy ramp) that creates multiple paths to re-rating.

Sources

Research only, not investment advice. Some metrics from secondary aggregators; verify against primary filings before any decision.